Loading...
Generating destination analysis
Catalyst Play
Featured in “Three Biotech Stocks to Buy Before ASCO's Biggest Data Drop”
ASCO May 29
CRISPR Therapeutics already made history with Casgevy, the first approved CRISPR gene-editing therapy. Now they're gunning for oncology — the largest market in biotech. ASCO data readouts could expand their pipeline into solid tumors. If the data is good, CRSP goes from gene-editing pioneer to oncology powerhouse.
The catalyst: The American Society of Clinical Oncology (ASCO) annual meeting — May 29 to June 2 in Chicago — is the most important event in cancer drug development. Over 40,000 oncology professionals gather for late-stage clinical trial data presentations that routinely move biotech stocks 30–50% in a single session. These three companies have the most anticipated data readouts at ASCO 2026, and the results will determine their trajectory for years.
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Key Numbers
Market Cap
$5B
P/E
N/A
Revenue Growth
+350.0%
Gross Margin
N/A
ROE
N/A
About CRISPR Therapeutics
Listed on the NASDAQ, CRISPR Therapeutics operates as a small-cap player in the biotech sector, offering investors focused access to biotech and genomics growth drivers. Pioneer of CRISPR gene-editing therapy with first approved treatment for sickle cell disease. With a $5B market capitalization and no current profitability, the business is characterized by exceptional revenue growth, reporting +350% revenue change year-over-year.
Expert Coverage
Unlock Full CRSP Analysis
Expert analysis and coverage for CRISPR Therapeutics
Upgrade to CompassFull access to 500+ ratings • $9/month
Price & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-05-10
More in Biotech & Genomics
LLY
Eli Lilly and Company
92
True North
Mixed
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
NYSE
MCap $750BRev +32%P/E 65ALNY
Alnylam Pharmaceuticals
90
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%BEAM
Beam Therapeutics
89
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3BDXCM
DexCom Inc.
89
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55